{{Chembox
| ImageFile = valspodar.svg
| ImageSize = 250px
| IUPACName = (3''S'',6''S'',9''S'',12''R'',15''S'',18''S'',21''S'',24''S'',30''S'',33''S'')-6,9,18,24-Tetraisobutyl-3,21,30-triisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(2''R'',4''E'')-2-methyl-4-hexenoyl]-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
| OtherNames = PSC833; PSC-833
|Section1={{Chembox Identifiers
| CASNo = 121584-18-7
| PubChem = 5281884
| ChemSpiderID = 4445174
| SMILES = C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C
| InChI = 1/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1
| InChIKey = YJDYDFNKCBANTM-QCWCSKBGBB
| StdInChI = 1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1
| StdInChIKey = YJDYDFNKCBANTM-QCWCSKBGSA-N
  }}
|Section2={{Chembox Properties
| C=63 | H=111 | N=11 | O=12
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}''

'''Valspodar''' ('''PSC833''') is an [[experimental cancer treatment]] and [[chemosensitizer]] drug.<ref name="WilkesAdes2004" />  It is a derivative of [[ciclosporin]] D. 

Its primary use is that of a [[P-glycoprotein]] inhibitor. Previous studies in animal models have found it to be effective at preventing [[Cancer|cancer cell]] resistance to [[chemotherapy|chemotherapeutics]], but these findings did not translate to clinical success.<ref name="TaoSotomayor2012" />

==Adverse effects==
Valspodar can cause nerve damage.<ref name="WilkesAdes2004" />

==References==
{{Reflist|refs=
<ref name="WilkesAdes2004">{{cite book|last1=Wilkes|first1=Gail|last2=Ades|first2=Terri B.|title=Consumers Guide to Cancer Drugs|url=https://books.google.com/books?id=d66G21_3tTUC&pg=PA226|accessdate=29 May 2013|year=2004|publisher=Jones & Bartlett Learning|isbn=9780763722548|page=226}}</ref>

<ref name="TaoSotomayor2012">{{cite book|last1=Tao|first1=Jian'guo|last2=Sotomayor|first2=Eduardo.|title=Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics |year=2012|publisher=Springer|isbn=9789400750289|page=335}}</ref>
}}

[[Category:Experimental cancer drugs]]
[[Category:Cyclic peptides]]